A Surprising Setback: FDA's Unexpected Rejection Jolts Disc Medicine and Patient Community In a significant blow to Disc Medicine and the patient community it serves, the U.S. Food and Drug Administration (FDA) has officially rejected the company's application for bitopertin, a novel drug
A patient's journey with pancreatic cancer too often begins not in a quiet doctor's office with a proactive screening, but in the chaotic, high-stakes environment of an emergency room. This sobering reality, where a life-altering diagnosis is delivered amid an acute medical crisis,
A significant legislative overhaul in 2025 has reshaped the landscape for thousands of Texans, transforming one of the nation’s most restrictive medical cannabis programs into a system poised for substantial growth and improved patient care. This industry report analyzes the pivotal reforms to the T
A sweeping set of regulatory proposals is poised to fundamentally reshape health plan offerings on the Affordable Care Act (ACA) marketplace, introducing a significant strategic shift toward what is known as "catastrophic coverage." While the administration presents these changes as a way
After more than a decade of relentless pursuit, PTC Therapeutics' decision to withdraw its application for Translarna marks a watershed moment for the company and the broader biopharmaceutical landscape for rare diseases. This conclusion to a protracted regulatory saga with the U.S. Food and
The rapid integration of sophisticated artificial intelligence into daily life now extends into one of its most personal and critical domains, with direct-to-consumer health applications promising a new era of accessible medical guidance. The proliferation of artificial intelligence represents a
